today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say ...

A local radio host is encouraging Tucsonans to consider genetic testing after it played a critical role in her own health ...

GeneDx is targeting a big market for its genetic testing: every newborn baby GeneDx has a big market in mind for its genetic testing: every newborn baby. The 24-year-old-company wants to make the ...

Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of Ambry Genetics, a company known for its genetic testing services that ...

GeneDx has a big market in mind for its genetic testing: every newborn baby. The 24-year-old-company wants to make the testing common at birth. The goal: Identify potential diseases or conditions ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic testing and precision medicine company, on Wednesday announced its groundbreaking study results on the Prequel Prenatal Screen with AMPLIFY ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies.

acting as a 'pre-screen' for BRCA mutations (BRCAm) that can then be confirmed with a regular genetic test. The germline BRCA (gBRCA) pre-screen programme has grown out of Owkin's ongoing ...